Chiron Health AI, a startup developing a breakthrough model in chronic disease management, has raised pre-seed funding led by SFC Capital.
The funding will enable Chiron Health AI to accelerate the launch of its fully integrated B2B product for healthcare payers, providers and pharma, and to develop a new data-driven self-care pathway designed to sit alongside medical care.
Co-founded by experienced entrepreneurs Carron Manning, Davide Crescenzi and Dr Karen Lawson within the Founders Factory venture studio, Chiron Health AI is building a breakthrough solution that uses artificial intelligence to analyse patient data profiles and recommend personalised self-care interventions that are most likely to be clinically successful, whilst measuring the impact.
These tailored recommendations are designed to maximise clinical outcomes and empower patients to effectively self-manage their condition whilst improving value-based outcomes for healthcare systems.
“This investment is a significant milestone in our journey to transform chronic disease management,” said Manning. “By integrating personalised AI-driven and evidence-based self-care into existing medical pathways, we aim to deliver better outcomes for patients and unlock value for healthcare providers and payers.”
SFC Capital, known for supporting early-stage companies with high growth potential, recognised Chiron Health AI’s mission to tackle one of healthcare’s most pressing challenges.
“Chiron Health AI is addressing a critical need in healthcare with its innovative, data-driven approach,” said Adam Beveridge, Investment Associate at SFC Capital. “We are excited to support their vision and see them make a meaningful impact on chronic disease management worldwide.”
Chiron Health AI says it is set to redefine how healthcare systems address long-term conditions, focusing on data-driven and personalised care that empowers patients and enhances clinical efficiency as part of the clinical workflow.
‘Humbled’ Emily Turner lands CEO role at HSBC Innovation Banking UK